Back to News
Market Impact: 0.2
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate
Source: marketbeat.com
Healthcare & BiotechCompany Fundamentals
Tango Therapeutics plans to start a global Phase III trial in the first half of 2027 testing vopimetostat with daraxonrasib as first-line treatment for patients with MTAP-deleted metastatic pancreatic ductal adenocarcinoma. The announcement provides a clinical-development timeline but no trial results or financial figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
TNGX0.55
More News
- Crude Oil Surges 4%; SLB Shares Jump Following Upbeat Q3 Earnings
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- Apple’s $2,000 iPhone Duo Debuts With Limited Supply
- Boeing 777 freighter output halted for two months over supplier row
- OpenAI Trims Target Value & Volvo Cars Cuts 2,500 Jobs
- Exclusive-Boeing supplier dispute has halted 777 freighter production for two months, sources say